| US5360897A
              (en)
            
            * | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad | 
        
          | US4902506A
              (en)
            
            * | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates | 
        
          | US5097020A
              (en)
            
            * | 1983-07-05 | 1992-03-17 | The University Of Rochester | Immunogenic conjugates | 
        
          | US4673574A
              (en)
            
            * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates | 
        
          | US4663160A
              (en)
            
            * | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria | 
        
          | US4762713A
              (en)
            
            * | 1983-07-05 | 1988-08-09 | The University Of Rochester | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers | 
        
          | US4761283A
              (en)
            
            * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates | 
        
          | US4695624A
              (en)
            
            * | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | 
        
          | US4808700A
              (en)
            
            * | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers | 
        
          | SE8405493D0
              (sv)
            
            * | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel | 
        
          | NZ214503A
              (en)
            
            * | 1984-12-20 | 1990-02-26 | Merck & Co Inc | Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates | 
        
          | US6074650A
              (en)
            
            * | 1985-06-24 | 2000-06-13 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses | 
        
          | US6024964A
              (en)
            
            * | 1985-06-24 | 2000-02-15 | Hoechst Aktiengesellschaft | Membrane anchor/active compound conjugate, its preparation and its uses | 
        
          | US4762822A
              (en)
            
            * | 1985-08-08 | 1988-08-09 | Ettinger Anna C | Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides | 
        
          | US4707543A
              (en)
            
            * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines | 
        
          | US4681761A
              (en)
            
            * | 1985-10-24 | 1987-07-21 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine | 
        
          | AU619443B2
              (en)
            
            * | 1986-04-21 | 1992-01-30 | Bioenterprises Pty. Ltd. | Immunopotentiation | 
        
          | CA1331355C
              (en)
            
            * | 1986-04-21 | 1994-08-09 | Bioenterprises Pty. Ltd | Immunopotentation | 
        
          | US5374426A
              (en)
            
            * | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions | 
        
          | US5300632A
              (en)
            
            * | 1986-11-18 | 1994-04-05 | Research Foundation Of State University Of New York | Method for purifying an outer membrane protein of Haemophilus influenzae | 
        
          | NZ223009A
              (en)
            
            * | 1986-12-31 | 1990-06-26 | Nl Rivm Of Thoven | Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens | 
        
          | US5976839A
              (en)
            
            * | 1987-03-13 | 1999-11-02 | Bioenterprises Pty Limited | Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules | 
        
          | US5785973A
              (en)
            
            * | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines | 
        
          | US5204098A
              (en)
            
            * | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates | 
        
          | US7118757B1
              (en)
            
            * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine | 
        
          | DE69012682T2
              (de)
            
            * | 1989-06-12 | 1995-04-06 | Merck & Co Inc | Verfahren zur Entfernung von bakteriellen Endotoxinen aus gram-negativen Polysacchariden. | 
        
          | CU22302A1
              (es)
            
            * | 1990-09-07 | 1995-01-31 | Cigb | Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales | 
        
          | EP0467714A1
              (en)
            
            * | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis | 
        
          | CA2047030A1
              (en)
            
            * | 1990-07-19 | 1992-01-20 | Allen I. Oliff | Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties | 
        
          | CA2059693C
              (en)
            
            * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae | 
        
          | CA2059692C
              (en)
            
            * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine | 
        
          | SK13494A3
              (en)
            
            * | 1991-08-13 | 1994-09-07 | Biotech Australia Pty Ltd | Immunostimulation | 
        
          | US5314811A
              (en)
            
            * | 1992-07-13 | 1994-05-24 | Merck & Co., Inc. | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide | 
        
          | US5736146A
              (en)
            
            * | 1992-07-30 | 1998-04-07 | Yeda Research And Development Co. Ltd. | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them | 
        
          | US6153406A
              (en)
            
            * | 1993-07-23 | 2000-11-28 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B | 
        
          | GB9422096D0
              (en)
            
            * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine | 
        
          | US6309646B1
              (en) | 1996-05-09 | 2001-10-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates | 
        
          | EP1109576B1
              (en)
            
            * | 1998-08-19 | 2009-10-21 | Baxter Healthcare SA | Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide | 
        
          | US6146902A
              (en)
            
            * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions | 
        
          | WO2002000249A2
              (en)
            
            * | 2000-06-29 | 2002-01-03 | Glaxosmithkline Biologicals S.A. | Multivalent vaccine composition | 
        
          | RU2175557C1
              (ru)
            
            * | 2000-09-04 | 2001-11-10 | Волков Александр Григорьевич | Способ предупреждения воспалительных заболеваний верхних дыхательных путей | 
        
          | GB0115176D0
              (en)
            
            * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines | 
        
          | WO2003094960A2
              (en)
            
            * | 2002-05-14 | 2003-11-20 | Chiron Srl | Mucosal combination vaccines for bacterial meningitis | 
        
          | CN1809380B
              (zh) | 2002-10-11 | 2010-05-12 | 启龙有限公司 | 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗 | 
        
          | GB0227346D0
              (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 | 
        
          | PT1587537E
              (pt) | 2003-01-30 | 2012-05-30 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos | 
        
          | GB0323103D0
              (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides | 
        
          | NZ546430A
              (en) | 2003-10-02 | 2009-04-30 | Novartis Vaccines & Diagnostic | Liquid vaccines for multiple meningococcal serogroups | 
        
          | GB0406013D0
              (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference | 
        
          | GB0408977D0
              (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins | 
        
          | GB0500787D0
              (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination | 
        
          | AU2005237289B2
              (en) | 2004-04-30 | 2011-08-04 | Glaxosmithkline Biologicals S.A. | Meningococcal conjugate vaccination | 
        
          | GB0409745D0
              (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins | 
        
          | GB0411387D0
              (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length | 
        
          | GB0413868D0
              (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates | 
        
          | BRPI0612654B8
              (pt) | 2005-06-27 | 2021-05-25 | Glaxosmithkline Biologicals Sa | método para conjugar um sacarídeo a uma proteína, e, conjugado sacarídeo-proteína | 
        
          | GB0524066D0
              (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii | 
        
          | SI1962899T1
              (sl) | 2005-12-22 | 2011-11-30 | Glaxosmithkline Biolog Sa | Pnevmokokna polisaharidna konjugatna vakcina | 
        
          | GB0607088D0
              (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine | 
        
          | EP2004225B1
              (en) | 2006-03-22 | 2012-04-25 | Novartis AG | Regimens for immunisation with meningococcal conjugates | 
        
          | GB0605757D0
              (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components | 
        
          | GB0612854D0
              (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis | 
        
          | CA2662064A1
              (en) | 2006-09-07 | 2008-03-13 | Glaxosmithkline Biologicals S.A. | Method of producing a combination polivirus vaccine | 
        
          | GB0700562D0
              (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides | 
        
          | EA201490303A1
              (ru) | 2007-05-02 | 2014-05-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина | 
        
          | ES2626662T3
              (es) | 2007-06-26 | 2017-07-25 | Glaxosmithkline Biologicals S.A. | Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae | 
        
          | FR2918671B1
              (fr)
            
            * | 2007-07-10 | 2010-10-15 | Sanofi Pasteur | Milieu de culture d'haemophilus influenzae type b. | 
        
          | GB0713880D0
              (en)
            
            * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification | 
        
          | GB0714963D0
              (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens | 
        
          | CN101951949B
              (zh) | 2007-10-19 | 2013-10-02 | 诺华股份有限公司 | 脑膜炎球菌疫苗制剂 | 
        
          | GB0818453D0
              (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom | 
        
          | ES2532946T3
              (es) | 2008-02-21 | 2015-04-06 | Novartis Ag | Polipéptidos PUfH meningocócicos | 
        
          | WO2010049806A1
              (en) | 2008-10-27 | 2010-05-06 | Novartis Ag | Purification method | 
        
          | GB0822634D0
              (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines | 
        
          | GB0822633D0
              (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation | 
        
          | EP2367568A2
              (en) | 2008-12-17 | 2011-09-28 | Novartis AG | Meningococcal vaccines including hemoglobin receptor | 
        
          | AU2010227219B2
              (en) | 2009-03-24 | 2014-02-27 | Glaxosmithkline Biologicals S.A. | Adjuvanting meningococcal factor H binding protein | 
        
          | US20120064103A1
              (en) | 2009-03-24 | 2012-03-15 | Novartis Ag | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates | 
        
          | CN109248313B
              (zh) | 2009-04-14 | 2023-01-17 | 葛兰素史密丝克莱恩生物有限公司 | 用于免疫接种以抵御金黄色葡萄球菌的组合物 | 
        
          | US20120135037A1
              (en) | 2009-06-01 | 2012-05-31 | Mizel Steven B | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same | 
        
          | CA2761733C
              (en)
            
            * | 2009-06-01 | 2019-01-08 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Reagents and methods for detecting influenza virus proteins | 
        
          | BR112012004275A2
              (pt) | 2009-08-27 | 2016-11-16 | Novartis Ag | polipeptídios híbridos incluindo sequências meningocócicas de fhbp | 
        
          | SG178904A1
              (en) | 2009-09-10 | 2012-04-27 | Novartis Ag | Combination vaccines against respiratory tract diseases | 
        
          | AU2010302344A1
              (en) | 2009-09-30 | 2012-04-26 | Novartis Ag | Expression of meningococcal fhbp polypeptides | 
        
          | BR112012010531A2
              (pt) | 2009-10-27 | 2019-09-24 | Novartis Ag | "polipeptídeos de modificação meningocócica fhbp" | 
        
          | GB0919690D0
              (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus | 
        
          | EP2519265B1
              (en) | 2009-12-30 | 2018-11-14 | GlaxoSmithKline Biologicals SA | Polysaccharide immunogens conjugated to e. coli carrier proteins | 
        
          | GB201003333D0
              (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions | 
        
          | GB201003922D0
              (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process | 
        
          | GB201003924D0
              (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition | 
        
          | GB201005625D0
              (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions | 
        
          | WO2011148382A1
              (en)
            
            * | 2010-05-28 | 2011-12-01 | Biological E Limited | An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol. | 
        
          | WO2011161653A1
              (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins | 
        
          | WO2012072769A1
              (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations | 
        
          | WO2012085668A2
              (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds | 
        
          | ES2681698T3
              (es) | 2011-03-02 | 2018-09-14 | Glaxosmithkline Biologicals Sa | Vacunas de combinación con menores dosis de antígeno y/o adyuvante | 
        
          | GB201103836D0
              (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process | 
        
          | GB201114923D0
              (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions | 
        
          | JP6170932B2
              (ja) | 2011-11-07 | 2017-07-26 | ノバルティス アーゲー | spr0096抗原およびspr2021抗原を含むキャリア分子 | 
        
          | PL3106176T3
              (pl) | 2011-12-06 | 2018-03-30 | Valneva Austria Gmbh | Związki glinu do stosowania w terapeutykach i szczepionkach | 
        
          | GB201121301D0
              (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method | 
        
          | EP2797624A1
              (en) | 2011-12-29 | 2014-11-05 | Novartis AG | Adjuvanted combinations of meningococcal factor h binding proteins | 
        
          | CN104519910B
              (zh) | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 | 
        
          | CN104159603A
              (zh) | 2012-03-08 | 2014-11-19 | 诺华股份有限公司 | 带有tlr4激动剂的联合疫苗 | 
        
          | SA115360586B1
              (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها | 
        
          | MX2015002717A
              (es) | 2012-09-06 | 2015-05-15 | Novartis Ag | Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina. | 
        
          | AU2013326584B2
              (en) | 2012-10-02 | 2016-12-01 | Glaxosmithkline Biologicals Sa | Nonlinear saccharide conjugates | 
        
          | CA2886938A1
              (en) | 2012-10-12 | 2014-04-17 | Glaxosmithkline Biologicals S.A. | Non-cross-linked acellular pertussis antigens for use in combination vaccines | 
        
          | AU2013351182C1
              (en) | 2012-11-30 | 2018-11-08 | Glaxosmithkline Biologicals Sa | Pseudomonas antigens and antigen combinations | 
        
          | EP2950819B1
              (en) | 2013-02-01 | 2018-03-28 | GlaxoSmithKline Biologicals SA | Intradermal delivery of immunological compositions comprising toll-like receptor agonists | 
        
          | EP4098276A1
              (en) | 2013-09-08 | 2022-12-07 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof | 
        
          | LT3110442T
              (lt) | 2014-02-28 | 2020-12-28 | Glaxosmithkline Biologicals Sa | Modifikuoti meningokokinio fhbp polipeptidai | 
        
          | EP3034516A1
              (en) | 2014-12-19 | 2016-06-22 | Novartis AG | Purification of streptococcal capsular polysaccharide | 
        
          | GB201518684D0
              (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine | 
        
          | WO2018042015A1
              (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae | 
        
          | US11027005B2
              (en) | 2016-10-20 | 2021-06-08 | Km Biologics Co., Ltd. | Method for producing Hib conjugate vaccine using PRP with lowered molecular weight | 
        
          | PL3544637T3
              (pl) | 2016-11-25 | 2021-06-14 | Glaxosmithkline Biologicals S.A. | Konjugaty natywnego omv-antygenu i ich zastosowanie | 
        
          | EP3544625A2
              (en) | 2016-11-25 | 2019-10-02 | GlaxoSmithKline Biologicals S.A. | Immunogenic conjugates and use thereof | 
        
          | US20210108002A1
              (en) | 2016-12-06 | 2021-04-15 | Glaxosmithkline Biologicals Sa | Purification Process For Capsular Polysaccharide | 
        
          | PE20191107A1
              (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos | 
        
          | CA3052621A1
              (en) | 2017-02-03 | 2018-08-09 | Schadeck, Eva Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof | 
        
          | WO2019070994A1
              (en) | 2017-10-04 | 2019-04-11 | Liffey Biotech Limited | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHODS OF USE | 
        
          | EP3607967A1
              (en) | 2018-08-09 | 2020-02-12 | GlaxoSmithKline Biologicals S.A. | Modified meningococcal fhbp polypeptides | 
        
          | CA3129425A1
              (en) | 2019-02-11 | 2020-08-20 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof | 
        
          | JP7239509B6
              (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 | 
        
          | JOP20200214A1
              (ar) | 2019-09-03 | 2021-03-03 | Serum Institute Of India Pvt Ltd | تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها | 
        
          | CA3155669A1
              (en) | 2019-09-27 | 2021-04-01 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof | 
        
          | EP3799884A1
              (en) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions | 
        
          | AU2021224078B2
              (en) | 2020-02-21 | 2024-01-18 | Pfizer Inc. | Purification of saccharides | 
        
          | GB202013262D0
              (en) | 2020-08-25 | 2020-10-07 | Glaxosmithkline Biologicals Sa | Vaccine Composition | 
        
          | CA3199094A1
              (en) | 2020-10-22 | 2022-04-28 | Pfizer Inc. | Methods for purifying bacterial polysaccharides | 
        
          | US20240000958A1
              (en) | 2020-11-13 | 2024-01-04 | Glaxosmithkline Biologicals Sa | Novel carriers and conjugation methods | 
        
          | GB202208089D0
              (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition | 
        
          | GB202208093D0
              (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition | 
        
          | GB202215414D0
              (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine | 
        
          | WO2024201324A2
              (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 
        
          | WO2024214016A1
              (en) | 2023-04-14 | 2024-10-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 
        
          | WO2024224266A1
              (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 
        
          | WO2025021710A1
              (en) | 2023-07-21 | 2025-01-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition | 
        
          | WO2025057078A1
              (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof | 
        
          | WO2025186705A2
              (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |